STERIS plc (Ireland) (STE) Stock forecasts
This article provides a brief overview of STERIS plc (STE), an Ireland-domiciled medical technology company specializing in sterilization services and infection prevention. It highlights an Argus report from November 18, 2026, which includes a current price of $254.76 for STE and offers access to a full report with a price target. The article also lists other related analyst reports for various companies.
Systech Expands Pharmaceutical Manufacturing Offering with Automated Serialization Stations for High-Performance Packaging Lines
Systech has launched two new automated serialization stations, the ST33 and ST34, designed for pharmaceutical manufacturers to enhance packaging line productivity and reduce operational complexity. These systems integrate critical processes like printing, verification, and tamper-evident sealing, running on Systech UniSeries® software. The ST33 is for space-constrained lines, while the ST34 combines multiple functions, aiming to improve efficiency and compliance in pharmaceutical packaging.
Form 4 STERIS plc For: Nov 13 Filed by: Madsen Julia
This article details a Form 4 filing for STERIS plc by Julia Madsen, Senior VP and GM, Life Sciences. The filing, dated November 13, 2026, reports a sale of 2,046 ordinary shares at a price of $260, leaving Madsen with 10,211 beneficially owned shares, of which 4,190 are restricted and will lapse on various dates through June 2029.
At $260 a share, STERIS (STE) executive Julia Madsen sells 2,046 shares.
STERIS plc's Sr. VP and GM, Life Sciences, Julia Madsen, sold 2,046 ordinary shares on November 13, 2026, at a price of $260 per share, totaling $532,000. Following this transaction, she directly holds 10,211 ordinary shares, of which 4,190 were restricted as of the sale date. The sale was reported in a Form 4 filing with the SEC, indicating a neutral filing impact and negative sentiment from an AI analysis.
NVRI: Enviri Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Enviri Corporation (NVRI) has settled a lawsuit against an insurance carrier related to its 2020 acquisition of Stericycle's environmental solutions business. The settlement will result in a $12 million cash payment to Enviri, expected in December 2026, and will be reflected in the company's fourth-quarter 2026 results. This payment is a one-time cash recovery for shareholders rather than a change to ongoing operations.
Steris PLC stock underperforms Tuesday when compared to competitors
Steris PLC's stock fell 1.46% to $257.41 on Tuesday, marking its second consecutive day of losses. This underperformance occurred during a generally weak trading session, with the S&P 500 Index and Dow Jones Industrial Average also declining.
If You Invested $1000 In Steris Stock 10 Years Ago, You Would Have This Much Today
Steris (NYSE: STE) has demonstrated strong performance over the last decade, outperforming the market by 1.87% annually with an average annual return of 14.74%. An initial investment of $1000 in STE stock 10 years ago would now be worth $3,927.28, highlighting the significant impact of compounded returns on cash growth over time.
Weekly Recap: STERIS prices $1.5B notes and Jefferies raises rating to Buy
STERIS plc (NYSE:STE) has priced $1.5 billion in senior notes to help fund its acquisition of Xodus Medical. Following this, Jefferies upgraded STERIS plc's rating from Hold to Buy and increased its price target to $305 from $232. The senior notes include $750 million at 5.65% due 2033 and $750 million at 5.875% due 2036.
Rocket Lab Just Hit 100 Launches. A Successful Neutron Debut Could Make 2027 Its Biggest Year Yet
Rocket Lab (RKLB) recently completed its 100th Electron launch, a milestone reached faster than any other commercial rocket. Despite this achievement, shares are down 12% this year, trading at $62. The company's path to a $100 share price in 2027, which would require a significant sales multiple and 62.5% gain, largely hinges on a successful debut of its Neutron rocket, which already has 16 missions booked and has seen its base price increase from $55 million to $70 million.
Form 144 STERIS plc For: 14 November By Investing.com
This article announces the filing of Form 144 for STERIS plc, dated November 14. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, indicates this financial action involving the company STERIS plc (STE).
$250,000 in Golub Capital and Hercules Capital: Why BDC Income Belongs in a Roth IRA
Holding Business Development Company (BDC) income, which is often taxed at ordinary rates, within a Roth IRA can lead to significant tax savings. For a $250,000 portfolio split between Golub Capital BDC and Hercules Capital, this could save approximately $6,000 annually in taxes for someone in the 24% federal bracket. These savings compound over time, potentially growing into a substantial amount over 10-20 years, making Roth IRAs a strategic choice for high-yield, ordinary-income BDC investments.
STERIS (NYSE:STE) Upgraded at Wall Street Zen
STERIS (NYSE:STE) has been upgraded from a "buy" to a "strong-buy" rating by Wall Street Zen. The company also received several "overweight" and "buy" ratings from other analysts, resulting in a consensus "Moderate Buy" rating with an average price target of $283.50. STERIS recently surpassed quarterly earnings expectations, reporting EPS of $2.94 against an estimated $2.68, and revenue of $1.59 billion compared to $1.56 billion expected, marking an 8.8% year-over-year increase.
Steris PLC | 4: Statement of changes in beneficial ownership of securities-Director Martin Paul Edward
This document from Steris PLC is a Statement of Changes in Beneficial Ownership of Securities, specifically Form 4, concerning Director Martin Paul Edward. It details modifications in his holdings of company securities, as required by regulatory bodies.
Home Depot or Lowe’s: Which Dividend Grower Wins for Long-Term Income?
This article compares Home Depot and Lowe's as dividend growth stocks for retirement income, concluding that Home Depot is the stronger pick for retirees due to its higher current yield and resilient Pro-driven sales growth during a housing slump. While Lowe's has a better dividend growth engine and coverage, Home Depot's steadiness, lower leverage, and reaffirmed guidance make it more appealing for immediate income and stability. The verdict is based on Home Depot winning two out of three categories: current income and housing-cycle exposure.
Steris PLC stock outperforms competitors on strong trading day
Shares of Steris PLC (STE) rose 4.29% to $264.32 on Friday, outperforming the mixed stock market where the Dow Jones Industrial Average rose and the S&P 500 Index fell. This increase broke a two-day losing streak for the stock.
Steris upgraded by Jefferies with a new price target
Jefferies has upgraded Steris (STE) from Hold to Buy, setting a new price target of $305.00. This bullish call on the medtech company was published on November 13, 2026, and is available via Quantisnow's real-time market data platform. The article also provides historical stock performance context following previous headlines related to Steris.
STERIS plc (NYSE:STE) Stock Now Rated "Moderate Buy" by Wall Street Brokerages
STERIS plc (NYSE:STE) has received a "Moderate Buy" rating from Wall Street brokerages, with five out of six analysts recommending the stock and an average 12-month price target of $276.33. The company recently surpassed quarterly earnings and revenue expectations, reporting EPS of $2.94 against an estimated $2.68, and revenue of $1.59 billion, an 8.8% year-over-year increase. Despite recent insider stock sales by the CFO and a director, institutional investors hold a significant 94.69% of shares.
STERIS (NYSE:STE) Stock: Insider Mohsen Sohi Sells 4,893 Shares
STERIS Director Mohsen Sohi sold 4,893 shares of company stock for approximately $1.24 million, reducing his position by 16.76%. This sale occurred shortly after STERIS reported strong quarterly earnings, beating analyst expectations for both EPS and revenue. The company also announced a quarterly dividend of $0.69 per share, and analysts maintain a "Moderate Buy" rating with an average price target of $276.33.
Form 8K STERIS plc For: 12 November By Investing.com
This article from Investing.com announces the filing of a Form 8K by STERIS plc on November 12. The brief report indicates the company's stock symbol is STE, which was down 1.10% at the time of publication. The content primarily serves as a placeholder for the SEC filing announcement.
Form 8K STERIS plc For: 12 November By Investing.com
STERIS plc filed a Form 8K on November 12, 2026. This financial filing provides an update on the company's activities. The article, published by Investing.com, reiterates the filing and includes general market data.
STERIS Prices $1.5 Billion Senior Notes to Help Fund Pending Acquisition
STERIS (STE) has priced $1.5 billion in senior notes, comprising $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036. The proceeds, along with term-loan borrowings and cash, are intended to fund the company's pending acquisition of Xodus Medical, related expenses, and general corporate needs. The offering is expected to close around November 24, 2026.
4,061 STERIS plc $STE Shares Sold by Villere ST Denis J & Co. LLC
Villere ST Denis J & Co. LLC reduced its stake in STERIS plc (NYSE:STE) by 4.1%, selling 4,061 shares, but still holds 93,935 shares valued at approximately $19.7 million. Other institutional investors also adjusted their positions in the medical equipment provider, which recently reported strong quarterly earnings and an increased dividend. Analysts maintain a "Moderate Buy" rating for STERIS with an average target price of $276.33.
Waste Management stock keeps 2026 outlook as healthcare margins improve
Waste Management maintained its 2026 outlook after reporting stronger healthcare profitability, which helped offset concerns about fuel costs and declining collection volumes. The company saw a 6.3% rise in revenue and a 5.8% increase in adjusted operating EBITDA in the third quarter, with management expecting full-year revenue and free cash flow at the high end of guidance. Healthcare Solutions' strong performance, supported by cost management and Stericycle integration synergies, was a key factor in these results.
Weekly Recap: Higher FY2027 EPS guidance and two-part notes offering
STERIS plc (NYSE:STE) reported a strong fiscal second quarter with revenue up 8.8% to $1.588 billion and adjusted EPS of $2.94, leading to a raised FY2027 adjusted EPS guidance of $11.35–$11.55. The company also announced a two-part senior notes offering and moderated its guidance for Applied Sterilization Technologies, citing the end of customer destocking. KeyBanc maintained an Overweight rating and raised its price target for STE to $284.
What STERIS (STE) Said on Its Q2 Earnings Call
STERIS (STE) raised its fiscal 2027 earnings outlook after reporting strong second-quarter revenue and profit, driven by tariff refunds and robust Life Sciences equipment shipments. The company now expects diluted EPS of $11.35 to $11.55 and maintained its full-year revenue growth forecast. STERIS also announced a planned acquisition of Xodus Medical to expand its consumables offering and a restructuring plan to achieve annualized savings.
Rakuten Investment Management Inc. Acquires 17,498 Shares of STERIS plc $STE
Rakuten Investment Management Inc. initiated a position in STERIS plc during the third quarter, purchasing 17,498 shares valued at approximately $3.69 million. STERIS reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.69 per share. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $276.33.
STERIS plc (STE) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for STERIS plc (STE), showing average monthly price returns from 2016 to 2026. It includes current stock data, an after-hours quote, and a link to the Q2 2027 earnings call replay. The page also features general market data and navigation options for Yahoo Finance.
Form 424B5 STERIS plc For: 6 November By Investing.com
The article "Form 424B5 STERIS plc For: 6 November" by Investing.com is a regulatory filing announcement. It indicates the publication of Form 424B5 by STERIS plc on November 6, 2026. The content primarily serves as a placeholder for the filing and does not contain detailed financial analysis or news beyond the announcement itself.
Form 424B5 STERIS plc For: 6 November By Investing.com
The article announces the filing of Form 424B5 by STERIS plc on November 6. It appears to be a procedural announcement related to financial disclosures. The content primarily consists of navigation, advertisements, and market data rather than detailed information about the filing itself.
Form 424B5 STERIS plc For: 6 November By Investing.com
Investing.com published a Form 424B5 filing for STERIS plc on November 6, 2026. This SEC filing is available for public viewing, indicating a regulatory update concerning the company. The article provides the title of the filing and mentions STERIS plc's stock symbol (STE), along with its current performance.
Form S-3ASR STERIS plc For: 6 November By Investing.com
This article announces that STERIS plc filed a Form S-3ASR with the SEC on November 6. An S-3ASR is an automatic shelf registration statement used by well-known seasoned issuers, allowing them to register securities for future offerings. The filing is noted by Investing.com.
STERIS plc (2TG.F) stock price, news, quote and history
The article provides a stock quote and basic information for STERIS plc (2TG.F) on Yahoo Finance. It shows the current price, a slight decrease, and indicates that the market is open. The page also offers navigation to various financial data sections for the company.
STERIS (NYSE:STE) Price Target Raised to $284.00
KeyCorp has raised its price target for STERIS (NYSE:STE) to $284.00 from $269.00, maintaining an "overweight" rating and suggesting a 13.4% upside. This follows STERIS's strong quarterly performance, where the company exceeded EPS and revenue expectations. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average target price of $276.33.
Form S-3ASR STERIS plc For: 6 November By Investing.com
This article reports on the filing of Form S-3ASR by STERIS plc on November 6th. The brief notice from Investing.com indicates this is a routine financial filing. No further details about the content of the filing or its implications are provided in the article.
Form S-3ASR STERIS plc For: 6 November By Investing.com
This article reports on the filing of Form S-3ASR by STERIS plc on November 6th. The form is a filing typically used by companies to register securities for a potential offering, indicating a financial or corporate action by STERIS plc. The article is brief and primarily serves as an announcement of this regulatory filing.
Steris (STE) files mixed shelf
Steris (NYSE: STE) has filed a mixed shelf offering, which includes Debt Securities, Guarantees of Debt Securities, Ordinary Shares, Preferred Shares, Warrants, and Units. This filing provides the company with flexibility to issue various types of securities in the future. The article also notes Steris's current stock price, analyst rating, and dividend yield.
Nanobiotix shares fall 2.5% and lose 12% in one week on the SBF 120
Nanobiotix shares declined by 2.42% to €26.62 at midday, extending their weekly drop to 12.2% on the SBF 120. This fall follows a period of correction in technology stocks and despite a recent 19% gain over the month. The company's cash position of €110.9 million is expected to finance operations until 2029.
STERIS Raises Full-Year EPS Guidance to $11.35-$11.55 as Tariff Refunds and Life Sciences Surge Drive 19% Adjusted EPS Growth
STERIS plc reported strong second-quarter fiscal 2027 results, with adjusted EPS rising 19% to $2.94, partly due to a $20 million tariff refund. The company raised its full-year adjusted EPS guidance to $11.35-$11.55, driven by the strong Q2 performance, lower interest expense, and the tariff refund. Life Sciences was a standout performer with 18% organic growth, while Healthcare showed solid growth and AST recovered from earlier challenges.
STERIS Secures $1.6 Billion Revolving Credit and $500 Million Acquisition-Linked Term Loan
STERIS plc announced new credit facilities, including a $1.6 billion revolving credit facility maturing in 2031 and a $500 million delayed draw term loan. The term loan is contingent upon the completion of the Xodus Medical, Inc. acquisition, and these new agreements replace a previous revolving credit agreement from 2024.
Steris cuts FY27 GAAP EPS guidance to $8.92-$9.12, misses estimates
Steris PLC has lowered its fiscal year 2027 GAAP earnings per share guidance to a range of $8.92-$9.12, falling below the consensus analyst estimate of $9.06. This revised forecast represents a reduction from the company's previous guidance of $9.00-$9.20. The downward adjustment indicates a tightening of expectations for the fiscal year.
STERIS earnings beat by $0.26, revenue topped estimates
STERIS (NYSE: STE) reported better-than-expected second-quarter results, with EPS of $2.94 surpassing analyst estimates by $0.26 and revenue of $1.6 billion exceeding the consensus estimate of $1.56 billion. The company's stock price closed at $247.91, showing a 4.40% increase over the last three months despite a -4.67% decline over the past year. InvestingPro rates STERIS's financial health as "great performance."
STERIS (NYSE:STE) Releases Quarterly Earnings Results, Beats Estimates By $0.27 EPS
STERIS (NYSE:STE) announced its quarterly earnings, reporting $2.94 EPS, significantly surpassing the consensus estimate of $2.67 by $0.27, and generating revenue of $1.59 billion against an estimated $1.56 billion. Following the positive report, shares of STERIS rose 7.5% to $248.69, and the company also declared a quarterly dividend of $0.69 per share. Analysts currently hold a "Moderate Buy" consensus rating for STERIS, with an average price target of $271.33.
Form 8K STERIS plc For: 4 November By Investing.com
This article reports on STERIS plc's (STE) Form 8K filing for November 4, 2026. The filing is a standard regulatory disclosure, indicating a significant event or change for the company. The article provides the title of the filing and mentions STERIS plc's stock performance.
Form 8K STERIS plc For: 4 November By Investing.com
This article reports on STERIS plc's (STE) Form 8K filing for November 4th. The brief news item indicates that the company submitted a Form 8K, a report used by public companies to announce major events that shareholders should know about. No specific details about the content of the 8K filing are provided in this announcement.
Form 8K STERIS plc For: 4 November By Investing.com
This article announces that STERIS plc filed a Form 8K on November 4th. The filing is provided by Investing.com, a financial markets news and analysis platform. The article provides the title of the filing and mentions STERIS plc's stock symbol STE with a 7.16% increase.
Steris (STE) Q2 Earnings and Revenues Surpass Estimates
Steris (STE) reported strong Q2 earnings of $2.94 per share, surpassing the Zacks Consensus Estimate of $2.67, and revenues of $1.59 billion, exceeding estimates by 1.54%. Despite the positive results, Steris shares have seen an 8.7% loss year-to-date, contrasting with the S&P 500's gain. The company holds a Zacks Rank #2 (Buy), indicating expected market outperformance in the near future.
AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS shares are soaring, what you need to know
Shares of AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS all saw significant jumps in value following election results that confirmed Democrats reclaimed majorities in the House and Senate. This outcome eased regulatory uncertainty regarding drug pricing policy, as Wall Street analysts now project a strengthening recovery for the biopharmaceutical sector. The shifting balance of power is seen as creating a more predictable regulatory climate, encouraging investments in pharmaceutical and biotechnology development.
AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS shares are soaring, what you need to know
Shares of AdaptHealth, Align Technology, Acadia Healthcare, DexCom, and STERIS rose after election results confirmed Democrats reclaimed majorities in Congress, easing regulatory uncertainty in the biopharmaceutical sector. Wall Street analysts expect a strengthened recovery for the sector as drug pricing legislation is deemed unlikely to dominate the new legislative agenda. Broader equity markets also rebounded, viewing congressional checks and balances as a stabilizing force for policy decisions and investments.
Alcon Inc. (ALC) stock price, news, quote and history
Alcon Inc. (ALC) is currently trading at $77.74, up 7.42%, with a market capitalization of $37.58 billion. The company, headquartered in Geneva, Switzerland, specializes in eye care products, operating through Surgical and Vision Care segments. Alcon has a 1-year target estimate of $81.98 and a recent "Buy" rating from Needham with a price target of $98.
Chairman of Utah Medical Products Kevin Cornwell Buys More Stock
The Chairman of Utah Medical Products, Kevin Cornwell, recently purchased US$67k worth of company stock at US$66.75 per share, representing the largest insider purchase in the last year. This transaction, though a minuscule percentage increase in his overall shareholding, indicates confidence in the company's future from an insider perspective, especially since the purchase was made close to the current stock price of US$70.02. Insiders collectively own about 7.2% of the company's shares.